A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (BELIEVE)
Status
Completed
Conditions
Urgency Incontinence
Urinary Bladder Diseases
Urinary Bladder Overactive
Urologic Diseases
Overactive Bladder
Treatments
Drug: Betmiga®
Details and patient eligibility
About
A study to understand the impact of Betmiga® on patients quality of life, satisfaction with treatment, how long patients remain on treatment, patterns of healthcare resource utilisation, and safety as prescribed by the physicians in routine clinical practice.
Full description
Single arm, hybrid model study, observing patients on Betmiga under conditions of routine clinical practice, with some element of retrospective data collection 2 years prior to enrolment of the study
Enrollment
863 patients
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Patients who have been diagnosed with OAB symptoms at Visit 1 of this study. OAB is defined by the International Urogynecological Association (IUGA)/International Continence Society (ICS) 2010 joint report as urinary urgency, with or without urinary incontinence, usually with frequency and nocturia, with no proven infection or other obvious pathology.
- Patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment.
Exclusion criteria
- Patients who are currently taking Betmiga®.
- Contraindication(s) as per the Betmiga® Summary of Product Characteristics (SPC).
Trial design
863 participants in 1 patient group
1. OAB patients taking Betmiga®
Description:
OAB patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment
Treatment:
Drug: Betmiga®
Trial contacts and locations
60
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems